MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

Home・Akcijų sąrašas・Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp

Atidarymo kaina

14.71 3.45

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

14.01

Max

14.42

Pagrindiniai rodikliai
By Trading Economics
Pajamos	4.2M -26M
Pardavimai	6.4M 59M
Pelno marža	-43.467
Darbuotojai	619
EBITDA	11M -18M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+3.02% upside

Dividendai
By Dow Jones
Kitas uždarbis	2025-11-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	392M 2B
Ankstesnė atidarymo kaina	11.26
Ankstesnė uždarymo kaina	14.71

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bullish Evidence

8.81 / 10.18 Palaikymas ir pasipriešinimas

Adaptive Biotechnologies Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-10-02 23:30; UTC

Karštos akcijos

Stocks to Watch: Rumble, Applied Materials, American Outdoor Brands

2025-10-02 21:21; UTC

Uždarbis

Applied Materials Expects New Export Rule to Hit 2026 Revenue by $600 Million

2025-10-03 00:00; UTC

Įsigijimai, susijungimai, perėmimai

Warren Buffett's Berkshire Comes to the Aid of Occidental Petroleum -- Again -- WSJ

2025-10-02 23:40; UTC

Rinkos pokalbiai

Gold Edges Higher, Aided by Risks U.S. Shutdown May Weaken Economy -- Market Talk

2025-10-02 23:39; UTC

Rinkos pokalbiai

Japanese Stocks May Edge Higher, Tracking Wall Street Gains -- Market Talk

2025-10-02 23:29; UTC

Įsigijimai, susijungimai, perėmimai

Vistra: Transaction Remains on Track to Close This Qtr or 1Q 2026 >VST

2025-10-02 23:29; UTC

Įsigijimai, susijungimai, perėmimai

Vistra: Received Regulatory Approval From FERC for Acquisition of Certain Subsidiaries Owning Seven Natural-Gas Generation Facilities From Lotus Infrastructure Partners >VST

2025-10-02 23:29; UTC

Įsigijimai, susijungimai, perėmimai

Vistra: Next Step in Acquisition of Gas Generation Fleet With Approval From Federal Energy Regulatory Commission

2025-10-02 23:00; UTC

Rinkos pokalbiai

Warehouse Needs Time to Restore Credibility With Investors -- Market Talk

2025-10-02 22:54; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Scales's JV Buyout Lauded by Bull -- Market Talk

2025-10-02 22:54; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Global Forex and Fixed Income Roundup: Market Talk

2025-10-02 22:46; UTC

Rinkos pokalbiai

Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

2025-10-02 22:46; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-10-02 21:17; UTC

Įsigijimai, susijungimai, perėmimai

Buffett Scores Win in Berkshire's Deal for Occidental Chemicals Unit -- Barrons.com

2025-10-02 20:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Energy & Utilities Roundup: Market Talk

2025-10-02 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-10-02 20:49; UTC

Įsigijimai, susijungimai, perėmimai

OpenAI's Latest Funding Deal Returns Focus to AI Economy, Lifting U.S. Stocks -- WSJ

2025-10-02 20:00; UTC

Įsigijimai, susijungimai, perėmimai

Legrand Signs Definitive Agreement To Acquire Avtron Power Solutions, A Global Provider Of Load Banks & Power Quality Solutions >LR.FR

2025-10-02 19:20; UTC

Rinkos pokalbiai

Natural Gas Snaps Winning Streak Despite Small Inventory Rise -- Market Talk

2025-10-02 19:10; UTC

Rinkos pokalbiai

Bank of Canada to Publish Inflation Dashboard in 2026 -- Market Talk

2025-10-02 19:04; UTC

Rinkos pokalbiai

Oil Futures Extend Losses as Markets Brace for Higher Output -- Market Talk

2025-10-02 18:46; UTC

Įsigijimai, susijungimai, perėmimai

Honeywell: Transaction Expected to Improve Annual Free Cash Flow by More Than $100 M Over Next Several Years and Then Decrease Over Time >HON

2025-10-02 18:46; UTC

Įsigijimai, susijungimai, perėmimai

Honeywell: Loss Will Be Excluded From Adjusted EPS >HON

2025-10-02 18:46; UTC

Įsigijimai, susijungimai, perėmimai

Honeywell: Estimated Impact of Divestiture Will Be One-Time Loss of About $115 M >HON

2025-10-02 18:45; UTC

Įsigijimai, susijungimai, perėmimai

Honeywell Will Have No Further Fincl Exposure to the Transferred Liabilities >HON

2025-10-02 18:45; UTC

Įsigijimai, susijungimai, perėmimai

Honeywell Utilized Portion of Cash From Resideo Indemnification and Reimbursement Agreement Termination to Fund Delticus Transaction >HON

2025-10-02 18:44; UTC

Įsigijimai, susijungimai, perėmimai

Honeywell: Delticus Assumed Full Responsibility for Administering and Resolving All Current and Future Asbestos-Related Claims >HON

2025-10-02 18:44; UTC

Įsigijimai, susijungimai, perėmimai

Honeywell and Delticus Contributed About $1.68 B in Cash, as Well as Certain Insurance Assets Related to Legacy Asbestos Liabilities >HON

2025-10-02 18:44; UTC

Įsigijimai, susijungimai, perėmimai

Honeywell: Transaction Strengthens Annual Free Cash Flow Generation >HON

2025-10-02 18:43; UTC

Įsigijimai, susijungimai, perėmimai

Honeywell Divested All Legacy Bendix Asbestos Liabilities, as Well as Certain Non-Bendix Asbestos Liabilities, to Delticus >HON

Akcijų palyginimas

Kainos pokytis

Adaptive Biotechnologies Corp Prognozė

Kainos tikslas

By TipRanks

3.02% į viršų

12 mėnesių prognozė

Vidutinis 15 USD 3.02%

Aukščiausias 20 USD

Žemiausias 11 USD

Remiantis 8 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Adaptive Biotechnologies Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

8 ratings

Pirkti

Laikyti

Parduoti

Remiantis 8 analitikų, pateikusių Adaptive Biotechnologies Corp akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

8.81 / 10.18Palaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

All events are bullish.

There is one bullish event.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.